RALOXIFENE VS. PUBERTY BLOCKERS FOR UNWANTED BREAST DEVELOPMENT IN ADOLESCENTS WITH OVARIES

What If You Can’t Get Puberty Blockers?

Puberty blockers (GnRH agonists; the most well-known option is “Lupron” or “leuprolide depot”) are often framed as the primary option for preventing unwanted breast development for adolescents with ovaries in gender affirming care. In many ways, they are the first line of treatment. GnRH agonists suppress ovarian estrogen production and pause pubertal progression. That means that breast development, menstrual cycles, and other estrogen-driven changes in the body are paused while the blocker is being used. Raloxifene is an alternative option.

In clinical practice, we are often working in situations where puberty blockers are delayed, denied, or simply not accessible. Increasingly, insurance companies are requiring FDA-approved indications for coverage. This is particularly concerning because gender affirming care relies heavily on prescribing medications in ways that are standard within clinical practice but not specifically labeled for this use. This shift is not just a barrier for transgender care. It is discriminatory and has broader implications across pediatric medicine, where prescribing outside of FDA labeling is common, necessary, and well-established across multiple specialties including oncology and endocrinology.

Because of these barriers, we are frequently faced with a different question: what can we offer patients who are actively progressing through puberty and do not have access to GnRH agonists right now?

This is where medications like raloxifene enter the conversation.

What do puberty blockers do in the body?

Puberty blockers work at the level of the hypothalamic-pituitary-gonadal axis. They tell the brain that the body does not need LH (luteninizing hormone) and FSH (follicle stimulating hormone.) Consequently, the brain does not instruct the body to make LH and FSH. When LH and FSH levels are lower, ovarian production of hormones are reduced. Without higher levels of estrogen, breast tissue does not continue to develop, and menstrual cycles typically stop.

The effect is what we call a “global pause”.

This means that all estrogen-driven pubertal changes are halted. For patients early in puberty who want to prevent further development of secondary sex characteristics, this is often the most effective intervention when it is available.

What does raloxifene do in the body?

Raloxifene does not suppress estrogen production. Ovaries continue to function, estrogen is still present in the body, and the hypothalamic-pituitary-gonadal axis remains active.

Instead, raloxifene works at the level of the estrogen receptor. It has tissue-specific effects, acting as an antagonist in breast tissue while maintaining estrogen-like effects in other areas such as bone.

In practical terms, this means that raloxifene may reduce or slow further breast tissue development, even while estrogen is still circulating in the body.

However, because estrogen production is not suppressed, raloxifene does not reliably stop menstrual cycles and does not pause puberty in a global way.

So how do we use raloxifene?

In adolescent gender affirming care, raloxifene is most commonly considered in a few specific clinical situations.

One of the most common situations is as a bridge while trying to access puberty blockers. Patients may be navigating insurance appeals, prior authorizations, or long wait times for specialty care. During this time, puberty continues. Breast development progresses. For some patients, this progression is a significant source of distress, particularly because breast development is only partially reversible.

In this context, raloxifene may be used to reduce or slow further breast development while access to GnRH agonists is being pursued. It does not provide the same level of suppression, but it may help mitigate ongoing changes during a period when waiting can result in permanent physical outcomes.

Raloxifene may also be used when puberty blockers are not accessible at all due to cost, insurance restrictions, or other systemic barriers. In these situations, it can offer a way to reduce the impact of estrogen on breast tissue even though it does not fully suppress puberty.

In addition, raloxifene can be part of an individualized treatment plan for patients whose goals do not align with full pubertal suppression. Not every patient wants a complete pause of puberty. Some are specifically looking to limit or reduce breast development while allowing other aspects of their body to continue developing. Raloxifene offers a way to more selectively influence these outcomes.

Raloxifene may also be used in combination with puberty blockers in certain situations. For patients who are expected to remain on GnRH agonists for a longer duration, or for those with specific concerns about bone health, the estrogen-like effects of raloxifene on bone may be considered as part of a strategy to support bone density while still limiting breast development.

What does raloxifene change?

Raloxifene primarily affects breast tissue by blocking estrogen’s action at the receptor level. Based on available data and clinical experience, it may slow further breast development and in some cases reduce existing breast tissue, although this varies by person. (For additional information on estrogen receptors in the context of encouraging estrogen-related changes in the body, see Gettin’ Nerdy on Gettin’ Curvy: Estradiol, Progesterone, and SERMs.)

There is some evidence to support using raloxifene from its use in other populations, including adolescents with gynecomastia or breast hypertrophy where similar medications have been used to reduce breast tissue. Gynecomastia is the non-cancerous growth of breast tissue in testosterone-predominant bodies. Breast hypertrophy is the rapid increase in size of breast connective tissue.

It is important to be clear that the data in transgender adolescents is limited. Much of our understanding is extrapolated from other clinical contexts, and outcomes are not predictable for every patient.

Raloxifene does not stop periods, does not suppress ovarian function, and does not halt overall pubertal progression.

For patients where menstrual suppression or broader pubertal suppression is desired, the addition of testosterone may be considered when appropriate based on patient goals, readiness, and clinical context. Testosterone can suppress menstrual cycles and prevent further estrogen-driven pubertal changes, and may be used in combination with or following raloxifene depending on the treatment plan.

Why not just wait for puberty blockers?

Because waiting is not neutral.

Breast development that occurs during this time may not be fully reversible. For many patients, this can lead to long-term dysphoria and may ultimately require surgical intervention.

From a clinical perspective, the question is not whether raloxifene is equivalent to puberty blockers. It is not.

The question is what we can do to reduce harm while patients are navigating systems that delay or deny care.

These use cases are grounded less in ideal protocols and more in the reality of practicing medicine within oppressed systems that restrict access to evidence-based care.

What about safety?

Raloxifene has a known safety profile in adult populations, particularly in the treatment of osteoporosis and breast cancer risk reduction. Risks include venous thromboembolism, hot flashes, and other systemic effects.

Data in adolescents is limited, and data in transgender adolescents is even more limited. As with much of gender affirming care, we are working with a combination of available evidence, physiology, and clinical experience.

This makes informed consent essential. Patients and families need to understand what we know, what we do not know, and what the realistic expectations are.

What about access?

Puberty blockers can be extremely difficult to access, especially without insurance that explicitly covers gender affirming care. They are sometimes financially impossible to access without support programs.

Raloxifene does require a prescription, but may not require prior authorization or review by insurance companies. For families with limited or no insurance coverage, it is significantly less expensive than blockers, often less than $0.50 a tablet (raloxifene at CostPlus and at the mail order pharmacy we work with most often.)

Where does this fit in gender affirming care?

Raloxifene is not a replacement for puberty blockers. It does not provide complete pubertal suppression, and it does not address all estrogen-driven changes.

However, it has a role in reducing unwanted breast development, particularly in situations where access to puberty blockers is delayed or restricted. It also expands the range of options available for individualized care, allowing treatment plans to better align with specific patient goals.

As emerging literature has noted, innovative approaches are often necessary in transgender healthcare, particularly when standard options are not accessible.

Final thoughts

Adolescent gender affirming care is not practiced in a vacuum. It exists within systems that limit access, restrict coverage, and disproportionately impact transgender and gender diverse youth.

Puberty blockers remain an important and well-supported option for suppressing pubertal progression. But when they are not accessible, we still have an obligation to provide care.

Raloxifene is one of the tools that may help us do that. Not perfectly, not completely, but in a way that acknowledges both the physiology of puberty and the reality that delaying care can have lasting consequences.

At QueerDoc we approach these decisions through individualized, consent-driven care that centers patient goals while being transparent about uncertainty and risk.

There is no one way to be trans. There is no one way to go through puberty. But there are ways to do this thoughtfully, and in a way that actually supports the person in front of us.

References

1. Martinkovich S, Shah D, Lobo S, Arnott J. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clinical Interventions in Aging. 2014;9:1437–1452. doi:10.2147/CIA.S66690
2. Duschek EJ, Gooren LJ, Netelenbos C. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol. 2004;150(4):539–546. doi:10.1530/eje.0.1500539
3. Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res. 2004;19(9):1518–1524. doi:10.1359/JBMR.040503
4. Nordt CA, DiVasta AD. Gynecomastia in adolescents. Curr Opin Pediatr. 2008;20(4):375–382. doi:10.1097/MOP.0b013e328306a07c
5. Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr. 2004;145(1):71–76. doi:10.1016/j.jpeds.2004.03.057
6. Kunath F, Keck B, Antes G, et al. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Med. 2012;10:96. doi:10.1186/1741-7015-10-96
7. Farkas HS, Jee YH, Szymczuk V, Leschek EW. Persistent gynecomastia due to short-term low-dose finasteride for androgenetic alopecia. JCEM Case Rep. 2024;2(5):luae050. doi:10.1210/jcemcr/luae050
8. Eugster EA, Rubin SD, Reiter EO, et al. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr. 2003;143(1):60–66.
9. Kreher NC, Eugster EA, Shankar RR. The use of tamoxifen to improve height potential in short pubertal boys. Pediatrics. 2005;116(6):1513–1515. doi:10.1542/peds.2005-0577
10. Jordan VC. The science of selective estrogen receptor modulators: concept to clinical practice. Clin Cancer Res. 2006;12(17):5010–5013. doi:10.1158/1078-0432.CCR-06-1136
11. Pang KC, Notini L, McDougall R, et al. Long-term puberty suppression for a nonbinary teenager. Pediatrics. 2020;145(2):e20191606. doi:10.1542/peds.2019-1606
12. Xu JY, O’Connell MA, Notini L, Cheung AS, Zwickl S, Pang KC. Selective estrogen receptor modulators: a potential option for non-binary gender-affirming hormonal care? Front Endocrinol (Lausanne). 2021;12:701364. doi:10.3389/fendo.2021.701364
13. Clark DBA, Metzger DL, Pang KC, St Amand C, Khatchadourian K. Individualized and innovative gender healthcare for transgender and nonbinary youth. Nat Rev Endocrinol. 2025;21(7):441–452. doi:10.1038/s41574-025-01113-z
14. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282(7):637–645. doi:10.1001/jama.282.7.637
15. RUTH Investigators. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol. 2002;90(11):1204–1210.
16. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295(23):2727–2741. doi:10.1001/jama.295.23.joc60074

Last reviewed 5/15/26.